These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 36494616)

  • 61. FMRP regulation of aggrecan mRNA translation controls perineuronal net development.
    Van't Spijker HM; Richter JD
    J Neurochem; 2024 Sep; 168(9):1909-1922. PubMed ID: 38225196
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells.
    Kumari D; Swaroop M; Southall N; Huang W; Zheng W; Usdin K
    Stem Cells Transl Med; 2015 Jul; 4(7):800-8. PubMed ID: 25999519
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The state of synapses in fragile X syndrome.
    Pfeiffer BE; Huber KM
    Neuroscientist; 2009 Oct; 15(5):549-67. PubMed ID: 19325170
    [TBL] [Abstract][Full Text] [Related]  

  • 64.
    Trajković J; Makevic V; Pesic M; Pavković-Lučić S; Milojevic S; Cvjetkovic S; Hagerman R; Budimirovic DB; Protic D
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672829
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Proteomics insights into fragile X syndrome: Unraveling molecular mechanisms and therapeutic avenues.
    Abbasi DA; Berry-Kravis E; Zhao X; Cologna SM
    Neurobiol Dis; 2024 May; 194():106486. PubMed ID: 38548140
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fragile X premutation and associated health conditions: A review.
    Tassanakijpanich N; Hagerman RJ; Worachotekamjorn J
    Clin Genet; 2021 Jun; 99(6):751-760. PubMed ID: 33443313
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The fragile X mutation impairs homeostatic plasticity in human neurons by blocking synaptic retinoic acid signaling.
    Zhang Z; Marro SG; Zhang Y; Arendt KL; Patzke C; Zhou B; Fair T; Yang N; Südhof TC; Wernig M; Chen L
    Sci Transl Med; 2018 Aug; 10(452):. PubMed ID: 30068571
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Epigenetics of fragile X syndrome and fragile X-related disorders.
    Kraan CM; Godler DE; Amor DJ
    Dev Med Child Neurol; 2019 Feb; 61(2):121-127. PubMed ID: 30084485
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A near normal distribution of IQ in Fragile X Syndrome.
    Schmitt LM; Nelson M; Shaffer RC; Erickson CA
    Sci Rep; 2024 Oct; 14(1):23058. PubMed ID: 39367109
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations.
    Primerano B; Tassone F; Hagerman RJ; Hagerman P; Amaldi F; Bagni C
    RNA; 2002 Dec; 8(12):1482-8. PubMed ID: 12515381
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mosaicism in Fragile X syndrome: A family case series.
    Saldarriaga W; González-Teshima LY; Forero-Forero JV; Tang HT; Tassone F
    J Intellect Disabil; 2022 Sep; 26(3):800-807. PubMed ID: 33998336
    [TBL] [Abstract][Full Text] [Related]  

  • 72. From FMRP function to potential therapies for fragile X syndrome.
    Sethna F; Moon C; Wang H
    Neurochem Res; 2014 Jun; 39(6):1016-31. PubMed ID: 24346713
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Fragile X syndrome and FMR1-dependent diseases - clinical presentation, epidemiology and molecular background].
    Landowska A; Rzońca S; Bal J; Gos M
    Dev Period Med; 2018; 22(1):14-21. PubMed ID: 29641417
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fragile X syndrome: a review of clinical and molecular diagnoses.
    Ciaccio C; Fontana L; Milani D; Tabano S; Miozzo M; Esposito S
    Ital J Pediatr; 2017 Apr; 43(1):39. PubMed ID: 28420439
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lysine acetylome profiling in mouse hippocampus and its alterations upon FMRP deficiency linked to abnormal energy metabolism.
    Wu YY; Yang C; Yan HJ; Lu P; Zhang L; Feng WC; Long YS
    J Proteomics; 2022 Oct; 269():104720. PubMed ID: 36089189
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [FMR1 PREMUTATION CARRIERS - ARE THEY REALLY ASYMPTOMATIC?].
    Elizur S; Berkenstadt M; Ries-Levavi L; Gruber N; Pinhas-Hamiel O; Hassin-Baer S; Raas-Rothschild A; Raanani H; Cukierman-Yaffe T; Orvieto R; Cohen Y; Gabis L
    Harefuah; 2018 Apr; 157(4):241-244. PubMed ID: 29688643
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions.
    Kim K; Hessl D; Randol JL; Espinal GM; Schneider A; Protic D; Aydin EY; Hagerman RJ; Hagerman PJ
    PLoS One; 2019; 14(12):e0226811. PubMed ID: 31891607
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The fragile X syndrome: exploring its molecular basis and seeking a treatment.
    Bardoni B; Davidovic L; Bensaid M; Khandjian EW
    Expert Rev Mol Med; 2006 Apr; 8(8):1-16. PubMed ID: 16626504
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BDNF in fragile X syndrome.
    Castrén ML; Castrén E
    Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Spontaneous rescue of a FMR1 repeat expansion and review of deletions in the FMR1 non-coding region.
    Erbs E; Fenger-Grøn J; Jacobsen CM; Lildballe DL; Rasmussen M
    Eur J Med Genet; 2021 Aug; 64(8):104244. PubMed ID: 34022415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.